Selective peroxisome proliferator-activated receptor (PPAR) α modulators (SPPARMα) may provide a promising future for the management of atherogenic dyslipidemia and atherosclerosis as well as other metabolic abnormalities [20]. Here, PPARA is linked to atherosclerosis.